Dr. McGregor on Immunotherapy Combinations in Kidney Cancer

Bradley McGregor, MD
Published: Friday, Apr 06, 2018



Bradley McGregor, MD, physician, Genitourinary Oncology program, Dana-Farber Cancer Institute, instructor of medicine, Harvard Medical School, discusses combinations of immunotherapy for patients with kidney cancer.

Two phase III trials that are investigating immunotherapy combinations are CheckMate-214 and IMmotion151. CheckMate-214 investigated nivolumab (Opdivo) and ipilimumab (Yervoy), whereas IMmotion151 investigated atezolizumab (Tecentriq) and bevacizumab (Avastin). The CheckMate-214 study saw impressive complete response (CR) rates of 16% for patients with PD-L1 expression.

IMmotion151 also had a CR rate of 9%. The most appealing aspect of that trial was the low toxicity profile. In CheckMate-214, it seemed to only work best for intermediate- and poor-risk patients, says McGregor. But, in the IMmotion151 study, there was a benefit across all subgroups, independent of risk status.

There are multiple ongoing phase III trials inspired by phase I data that showed impressive response rates. The hope is that those response rates translate into the phase III trials and improve CR rates.
 


Bradley McGregor, MD, physician, Genitourinary Oncology program, Dana-Farber Cancer Institute, instructor of medicine, Harvard Medical School, discusses combinations of immunotherapy for patients with kidney cancer.

Two phase III trials that are investigating immunotherapy combinations are CheckMate-214 and IMmotion151. CheckMate-214 investigated nivolumab (Opdivo) and ipilimumab (Yervoy), whereas IMmotion151 investigated atezolizumab (Tecentriq) and bevacizumab (Avastin). The CheckMate-214 study saw impressive complete response (CR) rates of 16% for patients with PD-L1 expression.

IMmotion151 also had a CR rate of 9%. The most appealing aspect of that trial was the low toxicity profile. In CheckMate-214, it seemed to only work best for intermediate- and poor-risk patients, says McGregor. But, in the IMmotion151 study, there was a benefit across all subgroups, independent of risk status.

There are multiple ongoing phase III trials inspired by phase I data that showed impressive response rates. The hope is that those response rates translate into the phase III trials and improve CR rates.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Moving Forward From the Status Quo for the Treatment of Soft Tissue Sarcoma: Key Questions & New Answers to Optimize OutcomesAug 16, 20181.5
Community Practice Connections™: Personalized Sequencing in Castration-Resistant Prostate Cancer: Bridging the Latest Evidence to the Bedside in Clinical ManagementAug 25, 20181.5
Publication Bottom Border
Border Publication
x